Bank of New York Mellon’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.97M | Buy |
98,129
+4,562
| +5% | +$91.5K | ﹤0.01% | 2753 |
|
|
2025
Q1 | $1.84M | Buy |
93,567
+3,992
| +4% | +$78.6K | ﹤0.01% | 2724 |
|
|
2024
Q4 | $2.02M | Sell |
89,575
-828
| -0.9% | -$18.6K | ﹤0.01% | 2749 |
|
|
2024
Q3 | $2.31M | Sell |
90,403
-23,706
| -21% | -$605K | ﹤0.01% | 2679 |
|
|
2024
Q2 | $2.67M | Buy |
114,109
+37,632
| +49% | +$879K | ﹤0.01% | 2638 |
|
|
2024
Q1 | $1.35M | Sell |
76,477
-3,652
| -5% | -$64.2K | ﹤0.01% | 2987 |
|
|
2023
Q4 | $1.11M | Sell |
80,129
-630
| -0.8% | -$8.72K | ﹤0.01% | 3128 |
|
|
2023
Q3 | $1.1M | Sell |
80,759
-165
| -0.2% | -$2.25K | ﹤0.01% | 3096 |
|
|
2023
Q2 | $1.65M | Buy |
80,924
+65,629
| +429% | +$1.34M | ﹤0.01% | 2938 |
|
|
2023
Q1 | $335K | Buy |
15,295
+2,288
| +18% | +$50.1K | ﹤0.01% | 3691 |
|
|
2022
Q4 | $213K | Sell |
13,007
-98
| -0.7% | -$1.6K | ﹤0.01% | 3947 |
|
|
2022
Q3 | $120K | Hold |
13,105
| – | – | ﹤0.01% | 4162 |
|
|
2022
Q2 | $64K | Sell |
13,105
-4,318
| -25% | -$21.1K | ﹤0.01% | 4307 |
|
|
2022
Q1 | $131K | Buy |
17,423
+12,758
| +273% | +$95.9K | ﹤0.01% | 4345 |
|
|
2021
Q4 | $42K | Hold |
4,665
| – | – | ﹤0.01% | 4515 |
|
|
2021
Q3 | $76K | Buy |
+4,665
| New | +$76K | ﹤0.01% | 4373 |
|
|
2021
Q2 | – | Sell |
-4,537
| Closed | -$153K | – | 4406 |
|
|
2021
Q1 | $153K | Sell |
4,537
-2,043
| -31% | -$68.9K | ﹤0.01% | 4105 |
|
|
2020
Q4 | $580K | Buy |
6,580
+2,981
| +83% | +$263K | ﹤0.01% | 3543 |
|
|
2020
Q3 | $293K | Sell |
3,599
-207
| -5% | -$16.9K | ﹤0.01% | 3726 |
|
|
2020
Q2 | $421K | Buy |
+3,806
| New | +$421K | ﹤0.01% | 3559 |
|